Analysis of nursing cooperation in the third phase clinical trial of acid inhibitor in the treatment of peptic ulcer bleeding
抑酸剂治疗消化性溃疡出血的Ⅲ期临床试验护理配合分析

摘要

目的 研究分析III 期临床试验护理配合抑酸剂治疗消化性溃疡出血的效果。方法 选取2017年1月-2017年12月期间在我院接收诊治的74例消化性溃疡出血患者，应用计算机进行随机分组，试验组（n=37）和对照组（n=37）。对照组采取常规药物治疗及护理干预；试验组采取新型抑酸剂治疗及综合护理干预。观察两组患者的治疗效果、凝血功能以及不良反应等情况。结果 试验组患者治疗的总有效率为94.59%显著高于对照组的78.38%，差异P<0.05有统计学意义。治疗护理前，两组患者凝血功能的凝血酶原时间（即 PT）、凝血酶时间（即 TT）、活化部分凝血活酶时间（即 APTT）指标相比，无差异性P>0,05，无统计学意义。治疗护理后，试验组患者的凝血功能指标水平显著小于对照组，差异P<0.05有统计学意义。试验组患者不良反应的发生率为5.41%与对照组的8.11%相比，差异P>0.05无统计学意义。结论 III 期临床试验护理配合新型抑酸剂治疗消化性溃疡出血的治疗效果更为理想，能有效帮助患者止血，且不良反应较少，安全性高，获得了临床的高度认可。

Abstract

Objective To study and analyze the effect of Phase III clinical trial nursing combined with antacid on peptic ulcer bleeding.
Methods 74 patients with peptic ulcer bleeding who were diagnosed and treated in our hospital from January 2017 to December 2017 were randomly divided into test group (n=37) and control group (n=37) by computer. The control group was treated with routine drugs and nursing intervention; The experimental group was treated with new acid inhibitor and comprehensive nursing intervention. The therapeutic effect, coagulation function and adverse reactions of the two groups were observed.
Results The total effective rate of the test group was 94.59%, which was significantly higher than that of the control group (78.38%, P<0.05). Before treatment and nursing, the indexes of prothrombin time (i.e. PT), thrombin time (i.e. TT) and activated partial thromboplastin time (i.e. APTT) of blood coagulation function in the two groups showed no difference P>0,05, with no statistical significance. After treatment and nursing, the level of coagulation function indicators in the test group was significantly lower than that in the control group, with a statistically significant difference of P<0.05. The incidence of adverse reactions in the test group was 5.41% compared with 8.11% in the control group (P>0.05).
Conclusion   Phase III clinical trial nursing combined with new acid inhibitor has a more ideal therapeutic effect in the treatment of peptic ulcer bleeding, which can effectively help patients to stop bleeding, with fewer adverse reactions and high safety, and has been highly recognized by the clinic.